| Execution period | Completion by Q4 FY2028; full operations by Q2 FY2029 |
|---|---|
| manufacturing production lines (injectable + oral solid + ophthalmic) | 10 production lines |
BSE filing, NSE: KPL. Summary written from the filing by ALFA Finder's alert engine.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,672.10
- Market cap
- ₹3,810 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.0×Sector 46.5×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Kwality Pharmaceuticals Q1 FY27 Results: Net Profit ₹25.6 Cr, Up 115.1% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹162.4 Cr (+45.7% YoY) and net profit of ₹25.6 Cr (+115.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹25.6 Cr · +115.1% YoY
Other capacity expansion announcements
All →Speciality Restaurants Capacity Expansion
Speciality Restaurants launched a new restaurant named WALTERS in Malad West, Mumbai, on October 28, 2026. The filing is a Reg 30 disclosure of a domestic restaurant launch with no monetary value stated.
- new restaurant outlets
- outlets
Goodluck India Capacity Expansion: ₹80 Cr Investment
Goodluck India's subsidiary Goodluck Defence and Aerospace approved adding Aerospace Components as a new line of business. The estimated investment is Rs 80 Crore, within a previously approved capital outlay.
- Value
- ₹80.00 Cr
Borosil Scientific Capacity Expansion: ₹70 Cr Investment
Borosil Scientific approved a Rs.70 Crore, 20 MT per day glass tubing furnace. Commercial production is expected by March 2028.
- Value
- ₹70.00 Cr
- Execution
- Commercial production expected by March 31, 2028
- borosilicate glass tubing production capacity
- 20.0 MT per day
Forbes Precision Tools and Machine Parts Capacity Expansion: ₹60 Cr Investment
Forbes Precision approved a Rs.60 Crore investment to add 10 lakh units annually within 1 to 1.5 years. Funding will combine internal accruals and debt.
- Value
- ₹60.00 Cr
- Execution
- 1 to 1.5 year
- production capacity
- 10.0 lakh units per annum
Diensten Tech Capacity Expansion
Diensten Tech's board approved incorporating a UAE subsidiary in IT consultancy, with the investment amount not yet fixed. Name, capital and incorporation date will be disclosed on completion.
- Execution
- Approximately 3 months from board approval, subject to regulatory approvals
Supreme Holdings & Hospitality (India) Capacity Expansion
Supreme Holdings approved a related-party joint development deal for a Panvel plot, pending shareholder approval. The project targets about 1 lakh sq ft saleable area.
- saleable area
- 100000.0 sq ft